Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Oral Mucositis
Interventions: AG013, Placebo; Biological · Other
Lead sponsor: Oragenics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more

Conditions: Alzheimer Disease
Interventions: florbetapir F 18; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 35 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: West Palm Beach, Florida • North East, Maryland • Clementon, New Jersey

Conditions: Cancer, Chronic Stress, Autonomic Dysfunction
Interventions: Hight intensity interval training, Cyclic Hyperventilation with Retention; Behavioral
Lead sponsor: University of Northern Colorado; Other
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Greeley, Colorado

Conditions: Multicentric Castleman's Disease
Interventions: Siltuximab, Placebo, Best Supportive Care (BSC); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 11
States / cities: Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 8 more

Conditions: Alzheimer Disease, Mild to Moderate Alzheimer Disease
Interventions: GRF6019; Drug
Lead sponsor: Alkahest, Inc.; Industry
Eligibility: 60 Years to 90 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Lemon Grove, California • Long Beach, California • San Diego, California + 7 more

Conditions: Colorectal Cancer Screening, Shared Decision Making
Interventions: Shared Decision Making for Colorectal Cancer Screening; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 206,721 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hyperlipidemia, Dyslipidemia
Interventions: NK-104-CR, Placebo, Livalo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 45
States / cities: Beverly Hills, California • Chino, California • Lincoln, California + 42 more

Conditions: Post-traumatic Stress Disorder
Interventions: Imagery Rehearsal, Sleep and Nightmare Management; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Smoking Cessation
Interventions: Rimonabant; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Malvern, Pennsylvania

Conditions: Thromboembolism
Interventions: Dabigatran, Warfarin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 2,867 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 18
States / cities: Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Glimepiride; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Bipolar Disorder, Depression
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 42
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more

Conditions: Anemia in Pregnancy, Preeclampsia
Interventions: Neevo® (a medical food), Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12); Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 21 Years to 39 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Sheffield, Alabama • Flowood, Mississippi • Gainesville, Texas

Conditions: Photoaging
Interventions: Astaxanthin 6 mg daily, Placebo; Dietary Supplement
Lead sponsor: Integrative Skin Science and Research; Industry
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
Interventions: brentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 32
States / cities: Gilbert, Arizona • Duarte, California • Stanford, California + 24 more

Conditions: Schizophrenia
Interventions: AVP-786, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Cerritos, California • Garden Grove, California • National City, California + 14 more

Conditions: Osteoarthritis, Knee
Interventions: TruMatch™ Personalized Solutions, Total Knee Arthroplasty with Conventional Instrumentation.; Other · Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Baltimore, Maryland • Saint Paul, Minnesota • Charlotte, North Carolina + 1 more

Conditions: Dry Eye Disease
Interventions: Lifitegrast, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 31
States / cities: Artesia, California • Hemet, California • Lancaster, California + 25 more

Conditions: Acute Pain, Headache, Musculoskeletal Pain
Interventions: Usual Care/Guideline, Opioid Justification, Provider Comparison; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 22,616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Spinal Cord Injury
Interventions: C-Brace II, Traditional Care KAFO intervention; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
Interventions: Ferric Maltol, Ferric Carboxy Maltose; Drug
Lead sponsor: Shield Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 17
States / cities: Dothan, Alabama • Tucson, Arizona • Gainesville, Florida + 14 more

Conditions: Atopic Dermatitis
Interventions: Delgocitinib cream, Delgocitinib cream vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Birmingham, Alabama • Encino, California • Los Angeles, California + 7 more

Conditions: Carpal Tunnel Syndrome
Interventions: Methylprednisolone Injection [Solu-Medrol], wrist splint; Drug · Device
Lead sponsor: Mercy Health Ohio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boardman, Ohio

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more

Search by objective public record fields.

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Can You Breathe Your Way To Better Health?

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

Colorectal Cancer Screening With Improved Shared Decision Making

Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

Cognitive Behavioral Treatments for Post-traumatic Stress Disorder (PTSD) Sleep Disturbance

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)

Secondary Prevention of Venous Thrombo Embolism (VTE).

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

A Retrospective Analysis of Neevo®/Neevo®DHA Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

Oral Supplementation of Astaxanthin on Skin Photoaging, Hydration and Elasticity

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

Alignment Comparison Between TruMatch™ Personalized Solutions and Conventional Total Knee Replacement Instrumentation

A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care

C-Brace II Spinal Cord Injury

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

A Comparison of Ultrasound-guided Steroid Injection With Wrist Splint in Carpal Tunnel Syndrome

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension